3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Breast
1
Conditions
Frailty
10
Neoplasms
7
Lymphoma
5
Breast Neoplasms
4
Prostatic Neoplasms
3
Lung Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Treatment Adherence and Compliance
1
Stomach Neoplasms
1
Solid Neoplasm
1
Sarcopenia
1
Sarcoma
1
Recurrence
1
Prostate Cancer Cured
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hepatic Malignancies
1
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Carboplatin
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Sunitinib
2
Standard of Care
2
Riluzole
2
Radiation Dose Hypofractionation
2
Prednisone
2
Pluvicto
2
Mitomycin
2
LDP-02
2
Infliximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Neoplasms
×
Geriatric Assessment
×
Clear all
NCT05509751
2026-04-28
SOAR
University of Toronto
Phase NA
Active not recruiting
60 enrolled